This is a working overview of quality control, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-07-19 and is reviewed periodically as new material appears.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA under peptide hormones |
| WADA class | S2 | Peptide hormones, growth factors, related substances, and mimetics |
| Approved therapeutic use | Not established | Clinical research did not lead to broad marketing approval |
| Common detection method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry |
| Sample preparation | Extraction and enrichment | Immunoaffinity or solid-phase extraction may be used |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Se-79, half-life of 327k years, is one of the long-lived fission products. Given the stability of its next lighter and heavier isotopes and the high cross section those isotopes exhibit for various neutron reactions, it is likely that the relatively low yield is due to Se-79 being destroyed in the reactor to an appreciable extent.
Glipizide, sold under the brand name Glucotrol among others, is an anti-diabetic medication of the sulfonylurea class used to treat type 2 diabetes. It is used together with a diabetic diet and exercise. It is not indicated for use by itself in type 1 diabetes. It is taken by mouth. Effects generally begin within half an hour and can last for up to a day. Common side effects include nausea, diarrhea, low blood sugar, and headache. Other side effects include sleepiness, skin rash, and shakiness. The dose may need to be adjusted in those with liver or kidney disease. Use during pregnancy or breastfeeding is not recommended. It works by stimulating the pancreas to release insulin and increases tissue sensitivity to insulin. Glipizide was approved for medical use in the United States in 1984. It is available as a generic medication. In 2023, it was the 42nd most commonly prescribed medication in the United States, with more than 15 million prescriptions.
[...] None of the participants to the conflict saw the events of 7–8 August in isolation, nor present them as isolated. How those events are interconnected is essential to determining the story." Fawn and Nalbandov paid attention to the report that during the military exercise "Kavkaz 2008" in the North Caucasus, which concluded in early August, a leaflet entitled "Soldier, know your probable enemy" (describing Georgia), was distributed among the Russian trainees. Fawn and Nalbandov argued: "The Russian military measures were part of a Russian strategy and possibly a genuine belief that Moscow was acting in accordance with, and upholding, international law and norms." Fawn and Nalbandov also argued, "Different events, and different interlinkages, create the story. What is common is that every event is used rhetorically as the ‘start’, which justifies retaliation." The researchers noted that "each military clash led to mutual blame by the belligerent parties: each side accused the other of opening the first salvo and characterized its actions only as a response." The researchers concluded, "The August war did not come out of nowhere. [...] The precise ignition of the war rests on specific timing in the late hours of 7 August and early hours of 8 August, and when and why Russian armor traveled through the Roki tunnel from the Russian Federation into Georgia." In August 2012, Scott C. Monje, senior editor of the Encyclopedia Americana, argued: "Thus, provocations and incidents had become commonplace over the course of several years, and they frequently occurred in the summer.
==== Shoulder disorders ==== A 2014 Cochrane review found insufficient evidence to determine whether electrotherapy was better than exercise at treating adhesive capsulitis. As of 2004, there is insufficient evidence to draw conclusions about any intervention for rotator cuff pathology, including electrotherapy; furthermore, methodological problems precluded drawing conclusions about the efficacy of any rehabilitation method for impingement syndrome.
Sources: en.wikipedia.org
8 October Police patrols in London are increased after videos emerge of what appears to be people celebrating a series of attacks launched by Hamas against Israel. Nathanel Young, a 20-year-old British man serving in the Israeli army, is killed in an attack by Hamas militants. The Israeli Embassy in London confirms that British-born Jake Marlowe, who was working in Israel as a security guard, is missing following the previous day's attacks. The final Wilko stores close in the UK. 9 October Sunak chairs an emergency COBRA meeting to discuss the escalating situation in Israel, and pledges further support for the country. The number of dead or missing Britons caught up in the Israel-Gaza attacks rises to more than 10; Nathanel Young and Bernard Cowan are the only two confirmed to have been killed. Addressing the congregation of a London synagogue, Sunak says that Britain stands with Israel, and that he will "stop at nothing" to keep Britain's Jewish community safe. Humza Yousaf, the First Minister of Scotland, condemns the attacks and expresses concern for his in-laws, who are "trapped" in Gaza after travelling there to visit relatives. 10 October In his speech to the Labour Party Conference, Sir Keir Starmer promises NHS reform, more police officers on streets, and 1.5 million new homes. The beginning of the speech is disrupted by a heckler on stage who throws black glitter over Starmer. After making contact with his parents-in-law in Gaza, Humza Yousaf calls for a humanitarian corridor to be established. The UK and Ireland are confirmed as joint hosts of Euro 2028.
=== 1970s === 1970: Australian geologist and palaeontologist Dorothy Hill became the first female president of the Australian Academy of Science. 1970: New Zealand geologist and palynologist Rosemary Askin the first New Zealand woman to undertake her own research programme in Antarctica. 1970: Spanish biochemist Margarita Salas discovered and characterized the Φ29 phage DNA polymerase. She was also the first scientific woman elected to the Royal Spanish Academy and was the first woman recipient of the Carlos J. Finlay Prize for Microbiology. 1970: Samira Islam became the first Saudi Arabian person to earn a PhD in pharmacology. 1970: American astronomer Vera Rubin published the first evidence for dark matter. 1970: Polish geologist Franciszka Szymakowska became widely known because of her unique and detailed geological drawings that are still used today. 1971: Romanian chemist Ecaterina Ciorănescu-Nenițescu became a member of the New York Chemical Society. She was noted for developing synthesis processes for antituberculosis drugs and insecticides and creating new substances using cytostatic grafting. 1973: American physicist Anna Coble became the first African-American woman to receive a PhD in biophysics, completing her dissertation at University of Illinois. 1974: Dominican marine biologist Idelisa Bonnelly founded the Dominican Republic Academy of Science. 1975: Indian chemist Asima Chatterjee was elected the General President of the Indian Science Congress Association. She simultaneously became the first female scientist ever elected a member of the congress.
(1914–2006), American physicist and chemist who won the 2002 Nobel Prize in Physics for detecting neutrinos emitted from the Sun Humphry Davy (1778–1829), British chemist, discovered several alkaline earth metals Serena DeBeer (born 1973), American chemist known for developing X-ray based spectroscopic probes of electronic structure Peter Debye (1884–1966), Dutch chemist who improved the theory of electrical conductivity in electrolyte solutions, winner of the 1936 Nobel Prize in Chemistry Johann Deisenhofer (born 1943), German biochemist who determined the three-dimensional structure of a protein complex found in photosynthetic bacteria, 1988 Nobel Prize in Chemistry Margarita del Val (born 1959), Spanish chemist, immunologist, and virologist, coordinator of the Salud Global ("Global Health") platform Nathalie Demassieux (1884–1961), French mineral chemist and academic who worked on the complex halogenated salts of lead Gautam Radhakrishna Desiraju (born 1952), Indian chemist known for work on crystal engineering and weak hydrogen bonds James Dewar (1842–1923), British chemist and physicist known for his invention of the vacuum flask and its usefor studying the liquefaction of gases François Diederich (1952–2020), Luxembourg chemist known for molecular recognition studies with biological receptors Otto Diels (1876–1954), German chemist, winner of the 1950 Nobel Prize in Chemistry for the Diels–Alder reaction, a method for cyclohexene synthesis Robert Dirks (1978–2015), American computational chemist known for work on DNA nanotechnology
In 1954, Mogens Schou of Denmark confirmed lithium's efficacy in a randomzied double-blind placebo-controlled study with his colleagues. Schou and Paul Baastrup organized other studies over the following years and decades and published a variety of research papers about lithium. At the time, lithium was a major advance. Before the advent of lithium, barbiturates were the standard treatment for mania. However, lithium was met with great resistance by British psychiatry. To Aubrey Lewis and Michael Shepherd, from the Institute of Psychiatry at Maudsley Hospital, lithium was ‘dangerous nonsense’. Michael Shepherd and Barry Blackwell called lithium a 'therapeutic myth.' The Maudsley psychiatrists had a history of debunking ineffective medical treatments. They claimed that Schou was biased because his brother, who experienced recurrent depressions since childhood, had a dramatic response to lithium. Schou felt that it had cured him. Largely through the research and other efforts of Mogens Schou and Paul Baastrup in Europe, and Samuel Gershon and Baron Shopsin in the U.S., resistance to lithium was slowly overcome. The American Psychiatric Association (APA) established a lithium task force chaired by Irvin M. Cohen, with members William Bunney, Jonathan Cole, Ronald R. Fieve, Samuel Gershon, Robert Prien, and Joseph Tupin. The recommendation of the lithium task force was to approve lithium. The application of lithium in manic illness was approved by the Food and Drug Administration in 1970, becoming the 50th nation to do so.
Lee, Nick; Bessho, Yoshitaka; Wei, Kenneth; Szostak, Jack W.; Suga, Hiroaki (2000). "Ribozyme-catalyzed tRNA aminoacylation". Nature Structural Biology. 7 (1): 28–33. doi:10.1038/71225. PMID 10625423. S2CID 1831912. Ramaswamy, Krishna; Saito, Hirohide; Murakami, Hiroshi; Shiba, Kiyotaka; Suga, Hiroaki (2004). "Designer Ribozymes: Programming the tRNA Specificity into Flexizyme". Journal of the American Chemical Society. 126 (37): 11454–11455. Bibcode:2004JAChS.12611454R. doi:10.1021/ja046843y. PMID 15366888. Passioura, Toby; Suga, Hiroaki (2017). "A RaPID way to discover nonstandard macrocyclic peptide modulators of drug targets". Chemical Communications. 53 (12): 1931–1940. doi:10.1039/C6CC06951G. PMID 28091672.
Sources: en.wikipedia.org
insertion sequence (IS) Also insertion element or simply insert. Any nucleotide sequence that is inserted naturally or artificially into another sequence. The term is used in particular to refer to the part of a transposable element that codes for those proteins directly involved in the transposition process, e.g. the transposase enzyme. The coding region in a transposable insertion sequence is usually flanked by short inverted repeats, and the structure of larger transposable elements may include a pair of flanking insertion sequences which are themselves inverted.
The meeting went from bad to worse, with Thiệu having a meltdown as he broke down in tears and hysterically accused Kissinger of plotting with the Soviet Union and China to betray him, saying he could never accept this peace agreement. Kissinger's statement that "Had we wanted to see you out, there would have been many easier ways by which we could have accomplished this" did not improve the mood. Thiệu later stated that he wanted to punch Kissinger in the face at that meeting. Thiệu refused to sign the peace agreement and demanded very extensive amendments that, as Kissinger reported to Nixon, "verge on insanity". Nixon ordered Kissinger to "push Thiệu as far as possible", but Thiệu refused to sign the peace agreement. Thiệu refused to see Kissinger the next day. Kissinger told one of Thieu's aides, Hoang Duc Nha, on the phone: "I am the special envoy of the President of the United States of America. You know I cannot be treated as an errand boy". Nha replied: "We never considered you an errand boy, but if that's what you think you are, there's nothing I can do about it". As Kissinger returned to Washington, one of his aides recalled: "In twenty-four hours, the bottom fell out". Though Nixon had initially supported Kissinger against Thiệu, two of his most influential advisers, namely his chief of staff, H.R. Haldeman and the Domestic Affairs Adviser John Ehrlichman, urged him to reconsider, arguing that Kissinger had given away too much and that Thiệu's objections had merit.
=== Small molecule inhibitors === Small molecules that are able to inhibit TGF-β induced EMT are under development. Silmitasertib (CX-4945) is a small molecule inhibitor of protein kinase CK2, which has been supported to be linked with TGF-β induced EMT, and is currently in clinical trials for cholangiocarcinoma (bile duct cancer), as well as in preclinical development for hematological and lymphoid malignancies. In January 2017, Silmitasertib was granted orphan drug status by the U.S. Food and Drug Administration for cholangiocarcinoma and is currently in phase II study. Silmitasertib is being developed by Senhwa Biosciences. Another small molecule inhibitor Galunisertib (LY2157299) is a potent TGF-β type I receptor kinase inhibitor that was demonstrated to reduce the size, the growth rate of tumors, and the tumor forming potential in triple negative breast cancer cell lines using mouse xenografts. Galunisertib is currently being developed by Lilly Oncology and is in phase I/II clinical trials for hepatocellular carcinoma, unresectable pancreatic cancer, and malignant glioma. Small molecule inhibitors of EMT are suggested to not act as a replacement for traditional chemotherapeutic agents but are likely to display the greatest efficacy in treating cancers when used in conjunction with them. Antagomirs and microRNA mimics have gained interest as a potential source of therapeutics to target EMT induced metastasis in cancer as well as treating many other diseases.
=== Transdifferentiation === Transdifferentiation refers to the conversion of one cellular phenotype to another. This phrase defines the overview of what dedifferentiation contributes to cell fates; firstly, dedifferentiation brings the cell back up the epigenetic landscape, and then the cell can “roll” down a new valley, thus re-differentiating into a new phenotype. This whole process of the cell fate changing from its original to a new fate is transdifferentiation. However, there is also a second definition of transdifferentiation, in which cells can be directly induced into a new cell type without necessitating dedifferentiation as an intermediate step.
Neanderthals, probably uncommonly, buried their dead. This may explain the abundance of fossil remains. The behaviour is not indicative of a religious belief of life after death because it could also have had non-symbolic motivations. The dead were buried in simple, shallow graves and pits, but special care seems to have been given to child graves. The graves of children and infants, especially, are associated with grave goods such as artefacts and bones. Some sites with multiple well-preserved Neanderthal skeletons may represent cemeteries. One grave in Shanidar Cave, Iraq, was associated with the pollen of several flowers that may have been in bloom at the time of deposition—yarrow, centaury, ragwort, grape hyacinth, joint pine and hollyhock. The medicinal properties of the plants led American archaeologist Ralph Solecki to claim that the man buried was a leader, healer, or shaman, and that "the association of flowers with Neanderthals adds a whole new dimension to our knowledge of his humanness, indicating that he had 'soul'". It is also possible the pollen was deposited by a small burrowing rodent after the man's death. Neanderthals were once thought to have ritually killed and eaten cave bears or other Neanderthals, but the evidence is circumstantial. In 2019, the Finlaysons reported that Neanderthals disproportionately butchered the golden eagle over any bird of prey or corvid species, and speculated that Neanderthals viewed the golden eagle as a symbol of power like some recent modern human societies did.
Sources: en.wikipedia.org
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.
Confirmatory detection typically uses liquid chromatography with mass spectrometry. Immunoassays may be used for screening, but mass spectrometry provides structural confirmation.
No widely approved therapeutic indication exists for AOD-9604. It has been investigated in clinical studies, but regulatory approvals for general medical use are not established.
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.